GSK In China: 13 Years Later - GSK in China: The Compliance Breakdown That Still Echoes 13 Years Later

GSK In China: 13 Years Later – GSK in China: The Compliance Breakdown That Still Echoes 13 Years Later

March 19, 2026

Thirteen years after the GSK China scandal exploded onto the global stage, its lessons remain as urgent as ever for compliance professionals and business leaders. In this podcast series, we revisit the case not simply as corporate history, but as a living cautionary tale about culture, incentives, third parties, investigations, and governance. Each episode explores what went wrong, why it went wrong, and how those failures still echo in today’s compliance and ethics landscape. Join me as we unpack the scandal and draw practical lessons for building stronger, more resilient organizations. In this inaugural episode, we take a deep dive into the 2013 GSK China bribery scandal and examine why it still stands as one of the most important case studies in corporate compliance, governance, and culture. Our hosts are Timothy and Fiona.

We unpack how a global pharmaceutical giant was alleged to have used travel agencies, fake conferences, false VAT receipts, and targeted marketing programs to channel illicit payments to doctors, officials, and other intermediaries, all while an internal whistleblower warning and a four-month internal investigation failed to detect the misconduct. The episode also explores the tension between polished global compliance structures and compromised local execution, showing how incentives, third-party relationships, and regional sales pressure can overwhelm formal controls. Most importantly, it asks a question that remains urgent today: are corporate compliance systems truly designed to find the truth, or can they create a false sense of security that allows misconduct to flourish undetected?

Key Highlights